Which means we rocket on approval as most bios trade @ 2-4 times sales. Then there's ACRX-04 entering PIII trials in late Q3 to early Q4 with another $300-400 million in sales coming to ACRX
if you look at other bio's you can see the sales ratio: vertex 5x sales. the smallest that i foung was 2.75 x sales.
the orignal u.s. sales estimeate without the european or other foreign data was 500 mill and the lowest was
400 mill. with 43 million shares out at 400 mill that is
3x = 28 bucks per share
5x = 46.51.
that is why i say 20+ on approval -- again with no other revenue or new products thown in.
at that doesn't take into consideration the 6+million shorts that will have to cover.
let's all take a moment and thank af.
$7 point move coming
How are you, my friend.? I know you hold some winners too. Diversification is a good thing, eh?
Sorry about today.